Cardiol Therapeutics Inc (CRDL): Next-Year EPS Estimate 52.55%
As of 2026-06-04, Cardiol Therapeutics Inc (CRDL) has a next-year EPS growth estimate of 52.55%.
On 2026-05-18, analyst consensus for CRDL's next-year EPS growth shifted from 49.77% to 52.55% — a positive change of 2.78 percentage points. The revised estimate has been sustained across 14 subsequent trading sessions. Current-year growth is projected at -23.91%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 52.55%
- EPS growth this year
- -23.91%
- EPS next quarter (est)
- -$0.07
- Last price
- $1.15
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 52.55% | -23.91% | -$0.07 | $1.15 |
| 2026-06-03 | 52.55% | -23.91% | -$0.07 | $1.12 |
| 2026-06-02 | 52.55% | -23.91% | -$0.07 | $1.15 |
| 2026-06-01 | 52.55% | -23.91% | -$0.07 | $1.22 |
| 2026-05-31 | 52.55% | -23.91% | -$0.07 | $1.22 |
| 2026-05-28 | 52.55% | -23.91% | -$0.07 | $1.28 |
| 2026-05-27 | 52.55% | -23.91% | -$0.07 | $1.28 |
| 2026-05-26 | 52.55% | -23.91% | -$0.07 | $1.30 |
| 2026-05-25 | 52.55% | -23.91% | -$0.07 | $1.32 |
| 2026-05-24 | 52.55% | -23.91% | -$0.07 | $1.32 |
| 2026-05-21 | 52.55% | -23.91% | -$0.07 | $1.31 |
| 2026-05-20 | 52.55% | -23.91% | -$0.07 | $1.30 |
| 2026-05-19 | 52.55% | -23.91% | -$0.07 | $1.26 |
| 2026-05-18 | 52.55% | -23.91% | -$0.07 | $1.28 |
| 2026-05-17 | 49.77% | -22.54% | -$0.07 | $1.32 |
| 2026-05-14 | 49.73% | -22.62% | -$0.07 | $1.37 |
| 2026-05-13 | 49.73% | -22.62% | -$0.07 | $1.38 |
| 2026-05-12 | 48.25% | -19.12% | -$0.06 | $1.35 |
| 2026-05-11 | 47.03% | -20.38% | -$0.07 | $1.34 |
| 2026-05-10 | 47.03% | -20.38% | -$0.07 | $1.32 |
| 2026-05-07 | 47.03% | -20.38% | -$0.07 | $1.30 |
| 2026-05-06 | 47.03% | -20.38% | -$0.07 | $1.32 |
| 2026-05-05 | 47.03% | -20.38% | -$0.07 | $1.31 |
| 2026-05-04 | 57.32% | -20.03% | -$0.06 | $1.33 |
| 2026-05-03 | 57.32% | -20.03% | -$0.06 | $1.37 |
| 2026-04-30 | 61.84% | -35.27% | -$0.06 | $1.38 |
| 2026-04-29 | 61.84% | -35.27% | -$0.06 | $1.31 |
| 2026-04-28 | 61.84% | -35.27% | -$0.06 | $1.37 |
| 2026-04-27 | 61.84% | -35.27% | -$0.06 | $1.40 |
| 2026-04-26 | 61.84% | -35.27% | -$0.06 | $1.40 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Cardiol Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Cardiol Therapeutics Inc (CRDL) has a next-year EPS growth estimate of 52.55%, based on analyst consensus.
When was the latest EPS estimate revision for CRDL?▾
The most recent revision occurred on 2026-05-18, when analysts adjusted the next-year EPS growth estimate from 49.77% to 52.55%.
What sector and industry does Cardiol Therapeutics Inc belong to?▾
Cardiol Therapeutics Inc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CRDL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Cardiol Therapeutics Inc (CRDL) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports